There are lots of great stocks in this sector. But one that investors should be watching closely right now is AbbVie (NYSE: ...

Here are four factors that led to this strong performance. First, AbbVie successfully protected its most important medicine, ...

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug ...

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug ...

Health care stocks have lagged the S&P 500 in 2025 thanks in part to U.S. policy uncertainty. However, health care stocks can often be a solid defensive play in an uncertain economy. People don' ...

Skyrizi is used to treat autoimmune and inflammatory conditions like Crohn’s disease and plaque psoriasis. It is administered via intravenous injection by a healthcare professional or subcutaneous ...

AbbVie’s ABBV key top-line drivers are its newer immunology medicines, Rinvoq and Skyrizi. Sales of both these drugs have effectively replaced the company’s flagship drug, Humira, which began facing ...